Overreaching. Over promising. Under delivering.
"Indication of efficacy designed to be available within 18 months" (Sept 2016)
- WE EXPECT TO KNOW WITHIN 12 MONTHS OF THE SUCCESS OF OUR MISSION (Nov 2016)
- AIM: • to have proof-of-concept by end-2017 • decision on indication for registration studies by end of 1Q-2018> https://www.noxopharm.com/site/PDF/1117_0/CorporatePresentationUpdated
Overreaching. Over promising. Under delivering. "Indication of...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.9¢ | $4.773K | 48.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20574 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 38542 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
